Hsbc Holdings PLC Grows Position in Guardant Health, Inc. $GH

Hsbc Holdings PLC grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 176.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,042 shares of the company’s stock after buying an additional 33,230 shares during the period. Hsbc Holdings PLC’s holdings in Guardant Health were worth $2,693,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Intech Investment Management LLC lifted its stake in Guardant Health by 37.3% in the 1st quarter. Intech Investment Management LLC now owns 60,187 shares of the company’s stock worth $2,564,000 after purchasing an additional 16,363 shares in the last quarter. Yorktown Management & Research Co Inc acquired a new stake in shares of Guardant Health in the second quarter valued at approximately $289,000. Osterweis Capital Management Inc. purchased a new position in Guardant Health during the first quarter worth approximately $12,634,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Guardant Health by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,236 shares of the company’s stock worth $3,035,000 after buying an additional 4,056 shares during the last quarter. Finally, Strs Ohio purchased a new stake in Guardant Health in the 1st quarter valued at $809,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GH shares. TD Cowen lifted their price target on Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Wednesday, October 8th. Wells Fargo & Company began coverage on shares of Guardant Health in a report on Monday, September 22nd. They issued an “overweight” rating and a $72.00 target price on the stock. Cowen reissued a “buy” rating on shares of Guardant Health in a research note on Thursday, October 30th. Finally, Evercore ISI lifted their price target on shares of Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.86.

Insider Transactions at Guardant Health

In other news, insider Terilyn J. Monroe sold 55,167 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $105.97, for a total transaction of $5,846,046.99. Following the completion of the transaction, the insider directly owned 20,920 shares in the company, valued at $2,216,892.40. This trade represents a 72.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John G. Saia sold 8,996 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $96.25, for a total value of $865,865.00. Following the completion of the sale, the insider owned 43,172 shares in the company, valued at $4,155,305. This represents a 17.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 368,228 shares of company stock valued at $24,835,525 over the last three months. 6.10% of the stock is currently owned by company insiders.

Guardant Health Price Performance

Shares of GH stock opened at $102.02 on Friday. Guardant Health, Inc. has a 1-year low of $29.91 and a 1-year high of $112.43. The firm has a market cap of $12.86 billion, a PE ratio of -31.78 and a beta of 1.58. The company has a 50-day moving average of $84.67 and a two-hundred day moving average of $63.25.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. The company’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.88) earnings per share. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.